All Oncology News

January 4th, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the approval of amivantamab as a treatment for patients with metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations who have experienced disease progression following platinum-based chemotherapy.

January 4, 2021 - A marketing authorization application has been submitted to the European Medicines Agency for the use of sotorasib in patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer.

January 4, 2021 — The pivotal phase 2/3 RINGSIDE trial, which is evaluating the potent, selective oral gamma secretase inhibitor AL102, has been permitted to proceed and can potentially be used as a registrational study for adolescent and adult patients with desmoid tumors.

January 4, 2021 - The biologics license application for the CAR T-cell product lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA, and a decision on the application has not yet been reached.

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

Rami Manochakian, MD, underscores the importance of looking for actionable alterations in lung cancer, barriers to genetic testing, and what is needed to overcome them.

The combination of telaglenastat plus cabozantinib failed to result in a significant improvement in progression-free survival in patients with advanced or metastatic renal cell carcinoma.

Ian E. Krop, MD, PhD, highlights the impact of the pivotal KATHERINE trial on the adjuvant treatment of patients with early-stage HER2-positive breast cancer and other recent advances that are moving the needle forward.

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

Bryon Lee, MD, PhD, discusses recent advances in surgical technique, approach, and perioperative care have made radical cystectomy significantly less morbid for patients with muscle invasive bladder cancer.

Joyce A. O’Shaughnessy, MD, highlights some of the most exciting updates in triple-negative breast cancer that emerged in 2020.

Neelima Vidula, MD, discusses the current and future utility of PARP inhibitors in triple-negative breast cancer, the promise of sacituzumab govitecan, and the need for germline genetic testing.

Joseph Kim, MD, discusses pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.

Omar Mian, MD, PhD, discusses selective bladder preservation in patients with muscle-invasive bladder cancer, biomarkers of response, and the utilization of hypofractionated radiation vs traditional approaches in this population.

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

December 30, 2020 - Bristol Myers Squibb has withdrawn nivolumab from the US market for the treatment of patients with small cell lung cancer who have experienced disease progression after a platinum-based chemotherapy and at least 1 other line of therapy.

Balazs Halmos, MD, discussed differences in the management of early- vs late-stage non–small cell lung cancer and the erasure of single-modality therapy across the field.

December 30, 2020 - The China National Medical Products Administration has approved surufatinib for the treatment of patients with non-pancreatic neuroendocrine tumors.

Alex A. Adjei, MD, PhD, discusses frontline treatment options for patients with advanced non–small cell lung cancer, as well as some of the nuances of selecting the optimal therapy.

Debra Patt, MD, highlights recent advancements and novel approaches in triple-negative breast cancer.

Shilpa Gupta, MD, discusses ongoing research with immunotherapy in bladder cancer, where research efforts should focus with regard to biomarkers, and other emerging agents that might move the needle forward.

December 30, 2020 - The phase 1/2 GOBLET trial will investigate the use of pelareorep in combination with atezolizumab in patients with metastatic colorectal and advanced or metastatic pancreatic and anal cancers.

Debu Tripathy, MD, discusses strategies that can be used to overcome ESR1 mutations in estrogen receptor–positive breast cancer.

December 29, 2020 - The FDA has granted an orphan drug designation to Annamycin for the treatment of patients with soft tissue sarcomas.

Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

R. Wendel Naumann, MD, discusses numerous investigations of PD-1 inhibitors in combination with PARP inhibitors or other targeted agents, as well as chemotherapy, and how it could finally start the next chapter of immunotherapy in gynecologic malignancies.

For the population of hospitalized patients with cancer, many of whom who have not contracted the disease, COVID-19 has real, immediate consequences; the pandemic has radically altered their end-of-life care.

December 28, 2020 - The FDA has granted priority review to a supplemental new drug application for lorlatinib for use as a frontline treatment in patients with ALK-positive metastatic non–small cell lung cancer.

Nicholas C. Rohs, MD, highlights the influx of clinical trials and the addition of immunotherapy in the adjuvant setting of lung cancer.